Data Analysis for Anti-Neoplastic Chemotherapy-Related Adverse Events Reported to the Korean Pharmacovigilance Regional Network |
Lee, Ju-Yeun
(College of Pharmacy and Institute of Pharmaceutical Science and Technology)
Jung, Jae-Woo (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) Kang, Hye-Ryun (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) Kim, Hyang-Sook (Department of Pharmacy, Seoul National University Hospital, Seoul National University College of Medicine) Cho, Sang-Heon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) |
1 | New Zealand Medicines and Medical Devices Safety Authority. Cisplatin injection, prescribing information [Internet]. New Zealand Medicines and Medical Devices Safety Authority, c2012 [cited 2012 Jun 5]. Available from: http://www.medsafe.govt.nz/profs/datasheet/c/ Cisplatinmaynepharmainj.pdf. |
2 | O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005;65:331-332. DOI ScienceOn |
3 | World Health Organization Uppsala Monitoring Center. The WHO adverse reaction terminology [Internet]. Uppsala: World Health Organization Uppsala Monitoring Center, c2012 [cited 2012 Jan 16]. Available from: http://www.umcproducts. com/graphics/3149.pdf. |
4 | World Health Organization. Collaborating Centre for Drug Statistics Methodology, ATC index with DDDs [Internet]. Oslo: WHO, c2008 [cited 2008 Dec 16]. Available from: http://www.whocc.no/atc_ddd_index. |
5 | National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]. Maryland (MD): National Cancer Institute, c2010 [cited 2010 June 20]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. |
6 | Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of Adverse Drug Reactions. New York: Oxford University Press, 1991:18-45. |
7 | Medina PJ, Shord SS. Cancer treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a Pathophysiologic Approach. 8th ed. New York: McGraw-Hill, 2011:2191-2228. |
8 | Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19. DOI ScienceOn |
9 | Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother 2003;4: 319-326. DOI ScienceOn |
10 | Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-306. DOI ScienceOn |
11 | Hospira. Methotrexate prescribing information [Internet]. Illinois (IL): Hospira, c2012 [cited 2012 Jun 5]. Available from: http://www.hospira.com/Images/432925_32-91319_1.pdf |
12 | U.S. National Library of Medicine. Nolvadex prescribing information [Internet]. Maryland (MD): U.S. National Library of Medicine, c2012 [cited 2012 Jun 5]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 3420. |
13 | Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019. |
14 | Ha T, Kwon SJ. Efficacy and safety profile of TS-1 or TS-1/CDDP in patients with advanced gastric cancer. J Korean Gastric Cancer Assoc 2006;6:139-145. DOI |
15 | Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323. DOI ScienceOn |
16 | Gähler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 2003;26:348-350. DOI ScienceOn |
17 | Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205. DOI ScienceOn |
18 | Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997;75:55-57. DOI |
19 | Morisaki T, Ohnita K, Takeshima F, et al. A case of sclerosing cholangitis caused by oral chemotherapy with S-1. Nihon Shokakibyo Gakkai Zasshi 2011;108:245-252. |
20 | Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218. DOI ScienceOn |
21 | Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004;18:275-280. DOI ScienceOn |
22 | Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997;53:19-22. DOI |
23 | Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117. DOI ScienceOn |
24 | Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21:3859-3866. DOI ScienceOn |
25 | Lim KH, Shin HT, Sohn HS, et al. Comparison of WHO-ART versus MedDRA, internationally standardized terminology of adverse drug reaction classification. Korean J Clin Pharm 2007;17:46-51. |
26 | Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008;98:1301-1304. DOI ScienceOn |
27 | Puche Canas E, Luna Del Castillo JD. Adverse drug reactions in patients visiting a general hospital: a meta-analysis of results. An Med Interna 2007;24:574-578. |
28 | Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003-1009. DOI |
29 | Ciorciaro C, Hartmann K, Kuhn M. Differences in the relative incidence of adverse drug reactions in relation to age? an evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center). Schweiz Med Wochenschr 1998;128:254-258. |